Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes

Ji Hyun Kim, Ji Hyun Ahn, Soo Kyung Kim, Dae Ho Lee, Hye Soon Kim, Ho Sang Shon, Hyun Jeong Jeon, Tae Hwa Kim, Yong Wook Cho, Jae Taek Kim, Sung Min Han, Choon Hee Chung, Ohk Hyun Ryu, Jae Min Lee, Soon Hee Lee, Min Jeong Kwon, Tae kyun Kim, Il Seong Namgoong, Eun Sook Kim, In Kyung Jung & 17 others Sung Dae Moon, Je Ho Han, Chong Hwa Kim, Eun Hee Cho, Ki Young Kim, Hee Baek Park, Ki Sang Lee, Sung Woo Lee, Sang Cheol Lee, Cheol Min Kang, Byung Sook Jeon, Min Seop Song, Seung Baik Yun, Hyung Keun Chung, Jong Ho Seong, Jin Yi Jeong, Bong Yun Cha

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims/Introduction: Early initiation of basal insulin therapy is recommended for normalizing fasting blood glucose in type 2 diabetes mellitus. However, basal insulin treatment might not adequately control postprandial glucose levels. The present study evaluated whether the combination of the α-glucosidase inhibitor, acarbose, and basal insulin improved blood glucose control under daily-life treatment conditions in a large sample of Korean patients. Materials and Methods: The present study was a multicenter, prospective, observational study under daily-life treatment conditions. A total of 539 patients with type 2 diabetes who were treated with basal insulin and additional acarbose were enrolled and followed up for 20 weeks. Changes in hemoglobin A1c, fasting and postprandial blood glucose were evaluated at baseline and at the end of the observation period. The physician and patient satisfaction of the combination treatment and safety were assessed. Results: Hemoglobin A1c decreased by 0.55 ± 1.05% from baseline (P < 0.0001). Fasting and postprandial blood glucose levels were reduced by 0.89 ± 3.79 and 2.59 ± 4.77 mmol/L (both P < 0.0001). The most frequently reported adverse drug reactions were flatulence (0.37%) and abnormal gastrointestinal sounds (0.37%), and all were mild in intensity and transient. In the satisfaction evaluation, 79.0% of physicians and 77.3% of patients were 'very satisfied' or 'satisfied' with the combined basal insulin and acarbose therapy. Conclusions: Combination therapy of basal insulin and acarbose in patients with type 2 diabetes improved glucose control, and had no drug-specific safety concerns, suggesting that the treatment might benefit individuals who cannot control blood glucose with basal insulin alone.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalJournal of Diabetes Investigation
Volume6
Issue number2
DOIs
Publication statusPublished - 2015 Mar 1

Fingerprint

Acarbose
Type 2 Diabetes Mellitus
Insulin
Glucose
Blood Glucose
Fasting
Therapeutics
Hemoglobins
Glucosidases
Physicians
Flatulence
Safety
Drug-Related Side Effects and Adverse Reactions
Patient Satisfaction
Observational Studies
Observation
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Kim, Ji Hyun ; Ahn, Ji Hyun ; Kim, Soo Kyung ; Lee, Dae Ho ; Kim, Hye Soon ; Shon, Ho Sang ; Jeon, Hyun Jeong ; Kim, Tae Hwa ; Cho, Yong Wook ; Kim, Jae Taek ; Han, Sung Min ; Chung, Choon Hee ; Ryu, Ohk Hyun ; Lee, Jae Min ; Lee, Soon Hee ; Kwon, Min Jeong ; Kim, Tae kyun ; Namgoong, Il Seong ; Kim, Eun Sook ; Jung, In Kyung ; Moon, Sung Dae ; Han, Je Ho ; Kim, Chong Hwa ; Cho, Eun Hee ; Kim, Ki Young ; Park, Hee Baek ; Lee, Ki Sang ; Lee, Sung Woo ; Lee, Sang Cheol ; Kang, Cheol Min ; Jeon, Byung Sook ; Song, Min Seop ; Yun, Seung Baik ; Chung, Hyung Keun ; Seong, Jong Ho ; Jeong, Jin Yi ; Cha, Bong Yun. / Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. In: Journal of Diabetes Investigation. 2015 ; Vol. 6, No. 2. pp. 219-226.
@article{314a0e17fced4b0797047dfbd099c434,
title = "Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes",
abstract = "Aims/Introduction: Early initiation of basal insulin therapy is recommended for normalizing fasting blood glucose in type 2 diabetes mellitus. However, basal insulin treatment might not adequately control postprandial glucose levels. The present study evaluated whether the combination of the α-glucosidase inhibitor, acarbose, and basal insulin improved blood glucose control under daily-life treatment conditions in a large sample of Korean patients. Materials and Methods: The present study was a multicenter, prospective, observational study under daily-life treatment conditions. A total of 539 patients with type 2 diabetes who were treated with basal insulin and additional acarbose were enrolled and followed up for 20 weeks. Changes in hemoglobin A1c, fasting and postprandial blood glucose were evaluated at baseline and at the end of the observation period. The physician and patient satisfaction of the combination treatment and safety were assessed. Results: Hemoglobin A1c decreased by 0.55 ± 1.05{\%} from baseline (P < 0.0001). Fasting and postprandial blood glucose levels were reduced by 0.89 ± 3.79 and 2.59 ± 4.77 mmol/L (both P < 0.0001). The most frequently reported adverse drug reactions were flatulence (0.37{\%}) and abnormal gastrointestinal sounds (0.37{\%}), and all were mild in intensity and transient. In the satisfaction evaluation, 79.0{\%} of physicians and 77.3{\%} of patients were 'very satisfied' or 'satisfied' with the combined basal insulin and acarbose therapy. Conclusions: Combination therapy of basal insulin and acarbose in patients with type 2 diabetes improved glucose control, and had no drug-specific safety concerns, suggesting that the treatment might benefit individuals who cannot control blood glucose with basal insulin alone.",
author = "Kim, {Ji Hyun} and Ahn, {Ji Hyun} and Kim, {Soo Kyung} and Lee, {Dae Ho} and Kim, {Hye Soon} and Shon, {Ho Sang} and Jeon, {Hyun Jeong} and Kim, {Tae Hwa} and Cho, {Yong Wook} and Kim, {Jae Taek} and Han, {Sung Min} and Chung, {Choon Hee} and Ryu, {Ohk Hyun} and Lee, {Jae Min} and Lee, {Soon Hee} and Kwon, {Min Jeong} and Kim, {Tae kyun} and Namgoong, {Il Seong} and Kim, {Eun Sook} and Jung, {In Kyung} and Moon, {Sung Dae} and Han, {Je Ho} and Kim, {Chong Hwa} and Cho, {Eun Hee} and Kim, {Ki Young} and Park, {Hee Baek} and Lee, {Ki Sang} and Lee, {Sung Woo} and Lee, {Sang Cheol} and Kang, {Cheol Min} and Jeon, {Byung Sook} and Song, {Min Seop} and Yun, {Seung Baik} and Chung, {Hyung Keun} and Seong, {Jong Ho} and Jeong, {Jin Yi} and Cha, {Bong Yun}",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/jdi.12261",
language = "English",
volume = "6",
pages = "219--226",
journal = "Journal of Diabetes Investigation",
issn = "2040-1116",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "2",

}

Kim, JH, Ahn, JH, Kim, SK, Lee, DH, Kim, HS, Shon, HS, Jeon, HJ, Kim, TH, Cho, YW, Kim, JT, Han, SM, Chung, CH, Ryu, OH, Lee, JM, Lee, SH, Kwon, MJ, Kim, TK, Namgoong, IS, Kim, ES, Jung, IK, Moon, SD, Han, JH, Kim, CH, Cho, EH, Kim, KY, Park, HB, Lee, KS, Lee, SW, Lee, SC, Kang, CM, Jeon, BS, Song, MS, Yun, SB, Chung, HK, Seong, JH, Jeong, JY & Cha, BY 2015, 'Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes', Journal of Diabetes Investigation, vol. 6, no. 2, pp. 219-226. https://doi.org/10.1111/jdi.12261

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes. / Kim, Ji Hyun; Ahn, Ji Hyun; Kim, Soo Kyung; Lee, Dae Ho; Kim, Hye Soon; Shon, Ho Sang; Jeon, Hyun Jeong; Kim, Tae Hwa; Cho, Yong Wook; Kim, Jae Taek; Han, Sung Min; Chung, Choon Hee; Ryu, Ohk Hyun; Lee, Jae Min; Lee, Soon Hee; Kwon, Min Jeong; Kim, Tae kyun; Namgoong, Il Seong; Kim, Eun Sook; Jung, In Kyung; Moon, Sung Dae; Han, Je Ho; Kim, Chong Hwa; Cho, Eun Hee; Kim, Ki Young; Park, Hee Baek; Lee, Ki Sang; Lee, Sung Woo; Lee, Sang Cheol; Kang, Cheol Min; Jeon, Byung Sook; Song, Min Seop; Yun, Seung Baik; Chung, Hyung Keun; Seong, Jong Ho; Jeong, Jin Yi; Cha, Bong Yun.

In: Journal of Diabetes Investigation, Vol. 6, No. 2, 01.03.2015, p. 219-226.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes

AU - Kim, Ji Hyun

AU - Ahn, Ji Hyun

AU - Kim, Soo Kyung

AU - Lee, Dae Ho

AU - Kim, Hye Soon

AU - Shon, Ho Sang

AU - Jeon, Hyun Jeong

AU - Kim, Tae Hwa

AU - Cho, Yong Wook

AU - Kim, Jae Taek

AU - Han, Sung Min

AU - Chung, Choon Hee

AU - Ryu, Ohk Hyun

AU - Lee, Jae Min

AU - Lee, Soon Hee

AU - Kwon, Min Jeong

AU - Kim, Tae kyun

AU - Namgoong, Il Seong

AU - Kim, Eun Sook

AU - Jung, In Kyung

AU - Moon, Sung Dae

AU - Han, Je Ho

AU - Kim, Chong Hwa

AU - Cho, Eun Hee

AU - Kim, Ki Young

AU - Park, Hee Baek

AU - Lee, Ki Sang

AU - Lee, Sung Woo

AU - Lee, Sang Cheol

AU - Kang, Cheol Min

AU - Jeon, Byung Sook

AU - Song, Min Seop

AU - Yun, Seung Baik

AU - Chung, Hyung Keun

AU - Seong, Jong Ho

AU - Jeong, Jin Yi

AU - Cha, Bong Yun

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Aims/Introduction: Early initiation of basal insulin therapy is recommended for normalizing fasting blood glucose in type 2 diabetes mellitus. However, basal insulin treatment might not adequately control postprandial glucose levels. The present study evaluated whether the combination of the α-glucosidase inhibitor, acarbose, and basal insulin improved blood glucose control under daily-life treatment conditions in a large sample of Korean patients. Materials and Methods: The present study was a multicenter, prospective, observational study under daily-life treatment conditions. A total of 539 patients with type 2 diabetes who were treated with basal insulin and additional acarbose were enrolled and followed up for 20 weeks. Changes in hemoglobin A1c, fasting and postprandial blood glucose were evaluated at baseline and at the end of the observation period. The physician and patient satisfaction of the combination treatment and safety were assessed. Results: Hemoglobin A1c decreased by 0.55 ± 1.05% from baseline (P < 0.0001). Fasting and postprandial blood glucose levels were reduced by 0.89 ± 3.79 and 2.59 ± 4.77 mmol/L (both P < 0.0001). The most frequently reported adverse drug reactions were flatulence (0.37%) and abnormal gastrointestinal sounds (0.37%), and all were mild in intensity and transient. In the satisfaction evaluation, 79.0% of physicians and 77.3% of patients were 'very satisfied' or 'satisfied' with the combined basal insulin and acarbose therapy. Conclusions: Combination therapy of basal insulin and acarbose in patients with type 2 diabetes improved glucose control, and had no drug-specific safety concerns, suggesting that the treatment might benefit individuals who cannot control blood glucose with basal insulin alone.

AB - Aims/Introduction: Early initiation of basal insulin therapy is recommended for normalizing fasting blood glucose in type 2 diabetes mellitus. However, basal insulin treatment might not adequately control postprandial glucose levels. The present study evaluated whether the combination of the α-glucosidase inhibitor, acarbose, and basal insulin improved blood glucose control under daily-life treatment conditions in a large sample of Korean patients. Materials and Methods: The present study was a multicenter, prospective, observational study under daily-life treatment conditions. A total of 539 patients with type 2 diabetes who were treated with basal insulin and additional acarbose were enrolled and followed up for 20 weeks. Changes in hemoglobin A1c, fasting and postprandial blood glucose were evaluated at baseline and at the end of the observation period. The physician and patient satisfaction of the combination treatment and safety were assessed. Results: Hemoglobin A1c decreased by 0.55 ± 1.05% from baseline (P < 0.0001). Fasting and postprandial blood glucose levels were reduced by 0.89 ± 3.79 and 2.59 ± 4.77 mmol/L (both P < 0.0001). The most frequently reported adverse drug reactions were flatulence (0.37%) and abnormal gastrointestinal sounds (0.37%), and all were mild in intensity and transient. In the satisfaction evaluation, 79.0% of physicians and 77.3% of patients were 'very satisfied' or 'satisfied' with the combined basal insulin and acarbose therapy. Conclusions: Combination therapy of basal insulin and acarbose in patients with type 2 diabetes improved glucose control, and had no drug-specific safety concerns, suggesting that the treatment might benefit individuals who cannot control blood glucose with basal insulin alone.

UR - http://www.scopus.com/inward/record.url?scp=84923695947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923695947&partnerID=8YFLogxK

U2 - 10.1111/jdi.12261

DO - 10.1111/jdi.12261

M3 - Article

VL - 6

SP - 219

EP - 226

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

SN - 2040-1116

IS - 2

ER -